Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAE609 MIC in Acute Uncomplicated Malaria
NCT01836458Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cipargamin in Plasmodium falciparum malaria, sponsored by Novartis. Started Jan 2014; status: completed.
02
Drugs
cipargamin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT01836458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836458.